<DOC>
	<DOCNO>NCT01540071</DOCNO>
	<brief_summary>This study evaluate benefit investigational drug , NRX 194204 slow down/stopping/reversing progression castration resistant taxane resistant prostate cancer .</brief_summary>
	<brief_title>Trial NRX 194204 Castration- Taxane-Resistant Prostate Cancer</brief_title>
	<detailed_description>Numerous study pre-clinical model human clinical trial clearly establish potential use rexinoids treatment prevention cancer . NRX 194204 , second generation rexinoid , highly potent specific activator RXRs . Because NRX 194204 significantly selective RXRs relative RARs first generation approve drug , associate few adverse event clinical use . This study seek investigate NRX 194204 monotherapy patient castration- taxane- resitant prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Histologically cytologically confirm prostate cancer Documented progression least one prior hormone treatment , AND least one taxane base chemotherapy regimen , patient 's refusal chemotherapy treatment Male , Age &gt; 18 year ECOG performance score 02 Adequate bone marrow , renal hepatic function Men childbearing potential must consent use barrier contraception treatment 90 day thereafter Prior treatment NRX 194204 bexarotene ( Targretin ) Presence parenchymal brain metastasis History prior malignancy within past 5 year exception curatively treat basal cell squamous cell carcinoma skin superficial bladder stage I stage II cancer complete remission least 12 month Patients history unstable newly diagnose angina pectoris , document history current serious arrhythmia congestive heart failure myocardial infarction within 6 month enrollment Known HIV hepatitis B C infection Life expectancy &lt; 3 month Patients history thyroid disease , pituitary disease treatment thyroid replacement hormone Patients history pancreatitis significant risk develop pancreatitis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hormone refractory prostate cancer</keyword>
	<keyword>HRPC</keyword>
	<keyword>Androgen independent prostate cancer</keyword>
	<keyword>CRPC</keyword>
	<keyword>Castration Taxane Resistant Prostate Cancer</keyword>
</DOC>